NASDAQ:IKT | Free Cash Flow | Inhibikase Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2020-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$12.06M$0.00-$12.06M
2025-12-31-$7.52M$0.00-$7.52M
2025-03-31-$4.1M$13,399.00-$4.12M
2024-12-31-$5.35M$0.00-$5.35M
2024-03-31-$3.87M$0.00-$3.87M
2023-12-31-$3.44M$0.00-$3.44M
2023-03-31-$5.97M
2022-12-31-$3.56M$0.00-$3.56M
2022-03-31-$3.93M
2021-12-31-$4.1M$0.00-$4.1M
2021-03-31-$3.93M
2020-12-31-$946,528.00
2020-03-31-$255,432.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$27.79M$13,399.00-$27.8M
2024-12-31-$19.15M$0.00-$19.15M
2023-12-31-$18.09M$14,238.00-$18.1M
2022-12-31-$17.35M$243,255.00-$17.59M
2021-12-31-$14.3M$0.00-$14.3M
2020-12-31-$1.13M